Secondary Breast Cancer

Debate between Clive Betts and Wendy Chamberlain

Thursday 11th June 2026 Westminster Hall

[Wendy Chamberlain (North East Fife) (LD)]

It is a pleasure to serve under your chairmanship, Mr Betts. Some people, both in this place and outside of it, say that politicians are out of touch, that they do not care and that they do not bring their lived experience to the Chamber. I want to thank the hon. Member for West Lancashire (Ashley Dalton) for everything that she did in her role as Health Minister and for her powerful speech. It should be essential watching for those who say otherwise about politicians’ intentions in this place.

I congratulate the hon. Member for City of Durham (Mary Kelly Foy) and my hon. Friend the Member for Wokingham (Clive Jones) on securing this debate, and I thank them for telling their own cancer experiences. Like most Members, I have been impacted by breast cancer in that my mother is a survivor. She was diagnosed when I was away from home for the first time at university. It was difficult for the family to receive that diagnosis and difficult for me, knowing that my mum was going through treatment while I was far away from home. I am pleased to say that she is still with us.

My colleague and friend in the Liberal Democrats in North East Fife, Councillor Fiona Corps, is currently stable after undergoing treatment for lobular breast cancer. She messaged me today to say she started her new meds yesterday. It is only two years since her daughter’s leukaemia fight. Fiona and her family have been through a lot. Her diagnosis brought me to speak to the lobular breast cancer campaign and I, like others, want to focus my remarks on that cancer in particular. Part of that is because, in relation to secondary breast cancer, the unmet clinical need of lobular breast cancer means the chances of it spreading are incredibly high. Indeed, for many who are diagnosed it has already spread by the time of their diagnosis.

It is important to note that this year marks 50 years since doctors first knew that lobular breast cancer was a distinct condition. I had not been born—just—we did not yet have Sony Walkmans, personal computers or mobile phones, “Don’t Go Breaking My Heart” was No. 1 for six weeks, and “Rocky” won best picture. I know it has been a long time since Scotland were in the World Cup, but this really was a long time ago. Here we are 50 years later in a world with advances that were unimaginable back then, but we have made painfully little progress on the diagnosis and treatment of lobular breast cancer.

As others have referenced, it is not like we think breast cancer is. As a woman, I have been taught to check for lumps—my mother’s experience made that more acute—but lobular cells grow in single lines that spread out over tissue. If a somebody did a lump check today, the chances are they would not spot it. Even more worryingly, if somebody goes for a mammogram, it will probably not show up there either. As others have referenced, 22 people are diagnosed with lobular breast cancer every day, but the reality is that we do not know how many people might be living with the disease and getting progressively more ill without treatment.

As of today, we still understand very little about it and there are no dedicated treatments for it. I am conscious that health is a devolved issue. I am standing here as a Scottish MP, but given the Minister’s responsibilities, I will note that the Government’s recent cancer action plan for England did not mention lobular breast cancer. We can say that other treatments are available, and Fiona and others are taking other treatments, but they are hit and miss. I have engaged with the Lobular Moon Shot Project and with Tristan—a constituent of my hon. Friend the Member for Horsham (John Milne)—and the story of his wife, Susan. She had eight different generic breast cancer treatments, none of which worked. Frankly, that lack of treatment kills people.

That is why lobular breast cancer is so relevant to the debate on secondary breast cancer. Not enough people know what to look for because it does not show up on tests, it is diagnosed late, and when it is diagnosed, there is not a dedicated treatment pathway for it. It is a recipe for a cancer spreading and we heard very powerfully from the hon. Member for West Lancashire what a diagnosis of secondary breast cancer means.

Unsurprisingly, there is still a lot that we do not know about what happens when the cancer spreads. We know it can spread to areas where other cancers do not like to, such as the outside membrane of the spine. We also know that the cells can lie dormant for years before starting to spread again. What we do not know is why any of that happens, how it can be identified, or how it can be stopped.

There could be hope. As others have referenced, researchers across this country are ready to take on this challenge. Importantly, there is cross-party support for getting this done; it is probably one of the most bipartisan campaigns in the history of this place. The Liberal Democrats are behind it; our leader, my right hon. Friend the Member for Kingston and Surbiton (Ed Davey), asked the Prime Minister about funding last summer. Indeed, I recently asked the then Secretary of State for Health and Social Care, the right hon. Member for Ilford North (Wes Streeting), about the project. He suggested that the money was there to fund the project, but work was needed on the programme of research. I say to the Minister: that is not how those involved with the project see it. This is a campaign that almost every Opposition MP supports, as well as huge numbers of those in the governing Labour party. Outwith this place, 84% of Labour voters surveyed in 2024 wanted lobular breast cancer research to be funded.

As others have said, £20 million over a five-year settlement equates to £238 per person for every person diagnosed over the next 10 years. Although I do not believe that life-changing research should be about a cost-benefit analysis, £238 is nothing compared with the costs of patients being out of the labour market and being treated over several years with the wrong thing—successfully or not.

I know that the Lobular Moon Shot Project is calling on devolved Governments to step up as well and provide £1 million per year for research to be carried out in their countries; the hon. Member for Strangford (Jim Shannon) referred to that, too. I call on the new Scottish Government and the new Cabinet Secretary for Health and Care to take this ask incredibly seriously.

I am sure that the Minister will refer to the current National Institute for Health and Care Research funding round. I do not want to pre-empt that—it is, of course, important— but it is not the same funding as is needed for the Lobular Moon Shot Project, which is research into the underlying biology of lobular breast cancer. Such research will remain weak until we know what it is we are trying to treat. We need funding for research into the underlying biology, so that lobular breast cancer can be identified, diagnosed and treated. That will improve outcomes drastically, including reducing the number of people with secondary breast cancer, which is the topic of this debate.

I will conclude by saying that my hon. Friend the Member for Wokingham has demonstrated very visibly that breast cancer is not simply a female issue, so I will end today by reflecting on the fact that anyone can get cancer. Many of those who do get cancer will make a full recovery. For some, cancer is something they will live with for the remainder of their life, but it will not be the condition from which they die. However, we have heard today that secondary breast cancer is decisive in terms of people’s life expectancy. We must let those women and men know that they are not alone.

[Mr Clive Betts (in the Chair)]

We now move on to the Front Benchers.